Results 11 to 20 of about 28,422 (269)

Omalizumab and IgE in the Control of Severe Allergic Asthma

Frontiers in Pharmacology, 2022
Omalizumab, a human immunoglobulin (Ig)G1 antibody against IgE, is a therapeutic agent for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of omalizumab should be considered as an option in step 5 of treatment for ...
Yasuhiro Gon, Shuichiro Maruoka, Kenji Mizumura   +2 more
doaj   +2 more sources

Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

Allergy. European Journal of Allergy and Clinical Immunology, 2023
Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission.
D. Thomas, V. McDonald, S. Stevens, E. Harvey, M. Baraket, Philip Bardin, J. Bowden, S. Bowler, Jimmy Chien, L. Chung, A. Gillman, M. Hew, S. Hodge, Alan James, C. Jenkins, C. Katelaris, G. Katsoulotos, D. Langton, Joy Lee, G. Marks, M. Peters, N. Radhakrishna, P. Reynolds, J. Rimmer, P. Sivakumaran, J. Upham, P. Wark, I. Yang, P. Gibson   +28 more
semanticscholar   +1 more source

Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacy

International Forum of Allergy and Rhinology, 2023
The heterogeneity of existing studies, along with the fact that there are no published head‐to‐head trials, are the main reasons for the lack of guidelines regarding the selection of the proper biologic in treatment of chronic rhinosinusitis (CRS) with ...
Georgios X Papacharalampous, J. Constantinidis, G. Fotiadis, N. Zhang, C. Bachert, M. Katotomichelakis   +5 more
semanticscholar   +1 more source

COMPARATIVE EFFECTIVENESS OF OMALIZUMAB, MEPOLIZUMAB, AND DUPILUMAB IN ASTHMA: A TARGET TRIAL EMULATION

Journal of Allergy and Clinical Immunology, 2023
Background: Multiple monoclonal antibodies are currently approved for the treatment of asthma. However, there is limited evidence on their comparative effectiveness.
A. Akenroye, Jodi B. Segal, G. Zhou, D. Foer, Lily Li, G. Alexander, C. Keet, J. Jackson   +7 more
semanticscholar   +1 more source

Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria. [PDF]

Photodermatol Photoimmunol Photomed
ABSTRACT Background Solar urticaria is a rare photodermatosis in which exquisite photosensitivity can require extreme behavioural adaptations, resulting in a substantial impact on quality of life (QoL). Omalizumab therapy has been demonstrated to improve several clinical outcome measures, but the impact on behavioural measures is poorly understood. Our
Parkin D, Marjanovic EJ, Farrar MD, Rhodes LE, Rutter KJ.   +4 more
europepmc   +2 more sources

Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials.

Journal of Allergy and Clinical Immunology, 2020
BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously ...
P. Gevaert, T. Omachi, J. Corren, J. Mullol, Joseph K. Han, Stella E. Lee, D. Kaufman, M. Ligueros‐Saylan, M. Howard, Rui Zhu, R. Owen, Kit Wong, L. Islam, C. Bachert   +13 more
semanticscholar   +1 more source

Omalizumab in IgE-mediated food allergy: A systematic review and meta-analysis.

Journal of Allergy and Clinical Immunology: In Practice, 2022
BACKGROUND A growing number of studies have shown encouraging results with omalizumab (OMA) as monotherapy and as an adjunct to oral immunotherapy (OMA+OIT) in patients with single/multiple food allergies. OBJECTIVES To evaluate the efficacy and safety
T. Zuberbier, R. Wood, C. Bindslev‐Jensen, A. Fiocchi, S. Chinthrajah, M. Worm, A. Deschildre, M. Fernández-Rivas, Alexandra F Santos, X. Jaumont, P. Tassinari   +10 more
semanticscholar   +1 more source

Allergic bronchopulmonary aspergillosis: diagnostic and treatment challenges [PDF]

, 2016
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder, occurring mostly in asthmatic and cystic fibrosis patients, caused by an abnormal T-helper 2 lymphocyte response of the host to Aspergillus fumigatus antigens.
CINICOLA, BIANCA LAURA, DUSE, MARZIA, Laitano, Rossella, LEONARDI, LUCIA   +3 more
core   +1 more source

Omalizumab-A review

Indian Journal of Dermatology, 2015
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.
Kiran Godse, Aayushi Mehta, Sharmila Patil, Manjyot Gautam, Nitin Nadkarni   +4 more
openaire   +3 more sources

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Dermatologic Therapy, 2023
Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development
T. Casale, A. Giménez-Arnau, J. Bernstein, M. Holden, Torsten Zuberbier, Marcus Maurer   +5 more
semanticscholar   +1 more source